This Government Contract opportunity from Department Of Health And Human Services was posted on November 17, 2025. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Top

Multiplexed Immune Assay Development for CBRN Threats

Closed

Federal

Submission Closed12/18/2025, 06:00:00 PM UTC

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 541711

Federal

Phase 2/3 Clinical Trial ExecutionThe contract pertains to the execution of Phase 2/3 clinical trials focused on acute pain management, requiring full management of trial operations including site selection, patient recruitment, data collection, and safety monitoring in strict compliance with FDA regulations. The work will be performed in Frederick, Maryland, with a post date of June 29, 2026, and a response deadline of July 30, 2026, at 5:00 PM. This is a subcontract under the Defense Health Agency, part of the Department of Defense, and falls under NAICS code 541711 for research and development in the physical, engineering, and life sciences. All activities must adhere to regulatory standards to ensure trial integrity, patient safety, and data reliability, with performance centered in Frederick, MD.

Defense Health Agency

POSTED

DEADLINE

Preclinical Animal Studies for Neurofibromatosis ResearchThe contract seeks to conduct preclinical in vivo studies using genetically engineered mouse models or alternative animal models of neurofibromatosis to assess the efficacy of therapeutic interventions, track tumor progression, and investigate underlying biological mechanisms. The work requires advanced expertise in animal modeling, tumor biology, and preclinical drug evaluation, with a focus on generating robust, reproducible data to support future clinical translation. All studies must be conducted in accordance with established ethical and scientific standards for animal research, with detailed documentation of methodologies, outcomes, and adverse events. This subcontract is issued under the Defense Health Agency Contracting Activity and falls under NAICS code 541711, indicating it supports research and development in the physical, engineering, and life sciences. The solicitation was posted on June 25, 2026, with a response deadline of September 22, 2026, and is open to qualified entities capable of executing complex preclinical studies. While the place of performance and point of contact details are unspecified, successful proposers must demonstrate capacity to manage animal facilities, comply with regulatory requirements, and deliver high-quality, timely results in support of neurofibromatosis research objectives under the Department of Defense.

Defense Health Agency Contracting Activity - Dhaca

POSTED

DEADLINE

Collaborative Biomedical Research ExecutionThis contract enables a collaborative biomedical research effort focused on neurofibromatosis, requiring coordinated hypothesis-driven investigations led by an Initiating Principal Investigator and a Partnering Principal Investigator. The work encompasses the design of experiments, generation of empirical data, and rigorous milestone-based progress reporting to ensure scientific rigor and accountability. The project is structured as a subcontract under the Defense Health Agency Contracting Activity, falling under the NAICS code for research and development in the physical, engineering, and life sciences, and is intended to advance understanding of neurofibromatosis through integrated scientific contributions. The solicitation was posted on June 25, 2026, with a response deadline of September 22, 2026, and is managed by the Department of Defense through its health research infrastructure. While no set-aside provisions or specific location details are provided, the emphasis is firmly on outcome-driven research with clearly defined deliverables tied to research milestones. The effort requires close alignment between the two principal investigators to ensure cohesive experimental planning, data integrity, and timely reporting, reflecting a strategic investment in translational medical science with potential implications for defense-relevant health conditions.

Defense Health Agency Contracting Activity - Dhaca

POSTED

DEADLINE

Data Management and Evaluation SupportThe contract titled Data Management and Evaluation Support is a subcontract under the Administration for Community Living, part of the Department of Health and Human Services, aimed at providing comprehensive support for the collection, management, analysis, and evaluation of research and program outcomes. The work must strictly adhere to federal standards to ensure data integrity, compliance, and quality reporting, with a focus on delivering actionable insights that inform program effectiveness and decision-making. The North American Industry Classification System code 541711 identifies this as scientific research and development services, underscoring the technical and analytical nature of the required efforts. Proposals must be submitted by the deadline of July 29, 2026, with the opportunity posted on June 22, 2026. The place of performance and specific office address are not specified, indicating flexibility in where the work may be conducted, though it must align with federal operational requirements. No set-aside type is designated, meaning the subcontract is open to all eligible subcontractors without preference for small businesses or other categories. Interested parties should review the official solicitation link for detailed submission guidelines and technical requirements, as success will depend on demonstrating robust methodologies in data handling, analytical rigor, and compliance with federal regulations governing research and program evaluation.

Administration For Community Living

POSTED

DEADLINE

Collaborative Research Partnership (Partnering PI Option)This contract establishes a collaborative research partnership where a Partnering Principal Investigator from an external institution will co-lead the research effort alongside the primary team, sharing equal responsibility for scientific direction, project management, and deliverables. Funding is jointly allocated between the participating institutions, ensuring aligned resources and mutual accountability for outcomes, with the work focused on health-related research under the Defense Health Agency Contracting Activity. The initiative falls under NAICS code 541711, indicating it is within the scientific research and development sector, and is structured as a subcontract to support integrated, multi-institutional innovation. The opportunity was posted on June 18, 2026, with a deadline for responses set for September 28, 2026, providing potential partners a defined window to submit proposals. The partnership is expected to be conducted in alignment with the mission of the Department of Defense, addressing critical health priorities through joint scientific leadership. There is no set-aside designation specified, meaning eligibility is open to qualified institutions regardless of size or status, and no specific location is designated for performance, allowing flexibility in where the research activities are carried out as long as the objectives are met collaboratively.

Defense Health Agency Contracting Activity - Dhaca

POSTED

DEADLINE

Kidney Cancer Clinical Research ExecutionThe contract titled Kidney Cancer Clinical Research Execution aims to advance clinical and translational research focused on kidney cancer through comprehensive scientific activities including study design, patient data collection, biomarker analysis, and therapeutic development. The work is intended to support the development of innovative treatments and diagnostic strategies by integrating clinical observations with laboratory research, ensuring findings are rapidly translated into improved patient outcomes. The project requires expertise in oncology research methodologies, rigorous data management, and interdisciplinary collaboration to address critical gaps in kidney cancer understanding and care. This subcontract is issued by the Defense Health Agency Contracting Activity under the Department of Defense and falls under NAICS code 541711, indicating it is related to research and development in the life sciences. The opportunity was posted on June 18, 2026, with a response deadline of September 28, 2026, providing potential applicants approximately three months to prepare and submit proposals. The place of performance and specific office address details are not specified, suggesting flexibility in location but requiring proposers to align with the overarching objectives of the Department of Defense’s medical research priorities. All work must demonstrate scientific excellence, feasibility, and direct relevance to advancing kidney cancer therapeutics within a clinical context.

Defense Health Agency Contracting Activity - Dhaca

POSTED

DEADLINE

Clinical Trial Design and Biostatistical SupportThe contract seeks specialized expertise to support clinical trial design and biostatistical analysis for orthopaedic trauma research funded by the Department of Defense, specifically under the U.S. Army Medical Research and Acquisition Activity. The work involves developing robust clinical trial methodologies, crafting statistical analysis plans, performing power analyses to ensure adequate sample sizes, and establishing data monitoring frameworks to ensure trial integrity and compliance with regulatory standards. Support must be tailored to the unique challenges of military-relevant trauma studies, including patient populations, deployment-related injuries, and the operational constraints of DoD medical settings. The opportunity is structured as a subcontract with a NAICS code of 541711, indicating it falls under research and development in the physical, engineering, and life sciences. The solicitation was posted on June 17, 2026, and responses are due by November 18, 2026. Performance is expected to occur within the broader DoD infrastructure, though no specific location is designated. There is no set-aside classification specified, and the contract is open to qualified entities capable of delivering high-level biostatistical and clinical trial methodological support in a defense medical research context.

Department Of The Army -- Usamraa

POSTED

DEADLINE

Preclinical Biomedical Research on Traumatic Orthopaedic InjuriesThis contract requires the conduct of preclinical biomedical research focused on bone healing, tissue regeneration, and orthopaedic trauma models using animal systems, with the goal of advancing medical solutions aligned with military needs. The work involves designing controlled experiments, collecting longitudinal data on injury response and recovery, and performing rigorous statistical and biological analysis to evaluate therapeutic interventions. All research must be tailored to simulate combat-related orthopaedic injuries and produce actionable insights applicable to field medical care and soldier recovery protocols. The effort is structured as a subcontract under the Department of the Army through USAMRAA, with a solicitation posted on June 17, 2026, and a response deadline of November 18, 2026. The project falls under NAICS code 541711 for research and development in the physical, engineering, and life sciences. Performance location and point of contact details are not specified, but the research must be executed in facilities capable of supporting high-standard animal modeling and biomechanical analysis. The ultimate objective is to generate validated preclinical data to inform the development of next-generation treatments for traumatic injuries sustained in military operations.

Department Of The Army -- Usamraa

POSTED

DEADLINE

Nanobody-Drug Conjugate Systems DevelopmentThe contract pertains to the licensing of the NanoFET platform to develop targeted nanobody-drug conjugates for the precision delivery of therapeutics using a modular scaffold designed to enhance specificity and efficiency in therapeutic distribution. This subcontract, issued by the Department of Energy through its contractor Triad, enables the recipient to leverage the proprietary NanoFET technology for advancing next-generation drug delivery systems with a focus on oncology and other targeted disease treatments. The project is centered in Los Alamos, New Mexico, with a response deadline of December 18, 2026, and falls under the NAICS code 541711 for research and development in biotechnology. The modular scaffold allows for customizable conjugation of nanobodies with therapeutic payloads, facilitating high-affinity targeting of disease markers while minimizing off-target effects. The agreement emphasizes technological innovation and the translation of advanced nanoscale platforms into clinically viable delivery systems.

Triad - DOE Contractor

POSTED

DEADLINE

Infectious Disease Vaccine DevelopmentThe contract involves licensing the NanoFET platform to enable rapid-response vaccine development against viral and bacterial pathogens, leveraging its unique adjuvant-free immune activation and modular antigen integration capabilities. This technology allows for swift adaptation to emerging infectious threats by streamlining the design and production of vaccines without relying on traditional immune-stimulating additives, significantly reducing development timelines and enhancing safety profiles. The work is structured as a subcontract under the Department of Energy, with performance centered at Los Alamos, New Mexico, and is targeted toward advancing national defense and public health preparedness through next-generation vaccine platforms. The opportunity is open for proposals until December 18, 2026, and falls under NAICS code 541711, indicating it targets research and development in the physical, engineering, and life sciences. The contracting entity is Triad, the DOE Contractor, and the initiative aligns with broader federal efforts to build resilient, scalable biodefense capabilities. Participants must demonstrate technical proficiency in the NanoFET platform, experience in infectious disease vaccine design, and the capacity to execute rapid development cycles under strict timelines. Success in this effort will contribute directly to scalable, next-generation immunization technologies capable of addressing current and future biological threats.

Triad - DOE Contractor

POSTED

DEADLINE

Modular Cancer Immunotherapy DevelopmentThe contract entails the license and development of the NanoFET platform for the creation of targeted cancer immunotherapies, leveraging its modular scaffold to deliver tumor-specific antigens and immune stimulators in a precise and effective manner. The work is focused on advancing next-generation immunotherapeutic approaches by engineering the platform to enhance immune recognition and response against cancer cells, with the goal of improving therapeutic outcomes and reducing off-target effects. The project requires collaboration to optimize the platform’s design, validate its efficacy in preclinical models, and prepare for subsequent clinical translation, all grounded in cutting-edge nanotechnology and immunological science. The contract is a subcontract under the Department of Energy, with performance centered in Los Alamos, New Mexico, 87545, and is classified under NAICS code 541711 for research and development in the physical, engineering, and life sciences. The solicitation was posted on June 17, 2026, with a response deadline of December 18, 2026, indicating a strategic timeline for proposal submission and evaluation. While details on set-aside status and point of contact are not provided, the project is positioned to align with national priorities in advanced biomedical innovation and cancer treatment, leveraging federal research infrastructure and expertise to drive transformative therapeutic solutions.

Triad - DOE Contractor

POSTED

DEADLINE

Antibody Development & LicensingThe contract involves the development, validation, and commercialization of monoclonal antibodies that specifically target bacterial membrane lipids. This work utilizes a nanodisc platform, which serves either as an immunogen or a screening tool, to enhance the effectiveness of antibody generation and assessment. The effort is positioned as a subcontract under the Department of Energy's Triad contractor, emphasizing a focus on innovative biotechnological approaches within a government research context. Work will be performed in Los Alamos, with the solicitation posted in mid-2026 and a response deadline toward the end of that year. The contract falls under NAICS code 541711, indicating its alignment with research and development in the physical, engineering, and life sciences. Although specific organizational and contact details are not provided, the contract is geared toward advancing antibody technologies through a combination of advanced immunological platforms and commercial application strategies.

Triad - DOE Contractor

POSTED

about 1 month ago

DEADLINE

in 5 months

General Info

Agency

Department Of Health And Human Services → Aspr Barda Division Contracts Management & AcqView Agency

NAICS

541711 - Research and Development in BiotechnologyView NAICS

Place of Performance

SC, 29486, USA

Set-Aside

NONE

Documents

(0)

No documents available

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

PhaseClosed

PostedNov 17

subcontract

Response DeadlineDec 18

Deadline has passed

Submission Closed

12/18/2025, 06:00:00 PM UTC

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

AgencyDepartment Of Health And Human Services → Aspr Barda Division Contracts Management & Acq

ContactsNo contacts available

OfficeN/A

Organization / Agency

Department Of Health And Human Services → Aspr Barda Division Contracts Management & Acq

View Agency Profile

Office AddressN/A

ContactsNo contact information available

Full Description

Design and develop a high-throughput multiplexed immune assay platform for detecting CBRN and infectious disease threats using minimally invasive samples. Focus on clinical validation, scalability, and commercialization readiness.